Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of ANH with HES 130/0.6 on Coagulation in Cardiac Surgery
NCT02502448Completed
- Sponsor
- Konkuk University Medical Center
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxyethyl starch 130/0.6 in mitral regurgitation (MR), mitral stenosis (MS) and tricuspid regurgitation (2 arms), sponsored by Konkuk University Medical Center. Primary endpoint: Maximal Clot Firmness. Started Jan 2016; status: completed.
02
Drugs
hydroxyethyl starch 130/0.6
03
Conditions
mitral regurgitation (MR)mitral stenosis (MS)tricuspid regurgitation
Beyond the preview
Go deeper on NCT02502448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502448.